51293-47-1

Basic information

• Product Name: BOC-SER(ME)-OH
• Synonyms: BOC-L-Ser（Me）-OH;(2S)-2-(tert-Butoxycarbonylamino)-3-methoxy-propanoic acid;Boc-O-methyl-L-serine dicyclohexylammonium salt≥ 98.5% (HPLC);(S)-N-BOC-2-AMINO-3-METHOXY-PROPIONIC ACID;N-ALPHA-T-BUTOXYCARBONYL-O-METHYL-L-SERINE;N-ALPHA-T-BUTOXYCARBONYL-O-METHYL-L-SERINE DICYCLOHEXYLAMMONIUM SALT;N-ALPHA-T-BOC-O-METHYL-L-SERINE;BOC-(S)-2-AMINO-3-METHOXYLPROPANOIC ACID
• CAS NO: 51293-47-1
• Molecular Formula: C₉H₁₇NO₅
• Molecular Weight: 219.23
• EINECS: 1533716-785-6
• Product Categories: unnatural amino acids;Serine [Ser, S];Boc-Amino Acids and Derivative;Boc-Amino acid series;API
• Mol File: 51293-47-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 355.8°C at 760 mmHg
• Flash Point: 169°C
• Appearance: /
• Density: 1.149g/cm³
• Vapor Pressure: 5.08E-06mmHg at 25°C
• Refractive Index: 1.46
• Storage Temp.: -15°C
• PKA: 3.52±0.10(Predicted)
• CAS DataBase Reference: BOC-SER(ME)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-SER(ME)-OH(51293-47-1)
• EPA Substance Registry System: BOC-SER(ME)-OH(51293-47-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 51293-47-1(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white crystals

InChI:InChI=1/C9H17NO5/c1-9(2,3)15-8(13)10-6(5-14-4)7(11)12/h6H,5H2,1-4H3,(H,10,13)(H,11,12)/t6-/m0/s1

Upstream product

• 75-18-3 dimethylsulfide 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 4219-94-7 DL-3-methoxy-alanine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 69912-63-6 boc-β-methoxyalanine dicyclohexylamine 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 183793-47-7 (S)-2-tert-butoxycarbonylamino-3-methoxy-propionic acid benzyl ester 
• 134167-07-0 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-methoxypropanoate 
• 74-88-4 methyl iodide 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 336100-47-1 O-Methyl-L-serin-hydrochlorid 

Downstream Products

• 183793-47-7 (S)-2-tert-butoxycarbonylamino-3-methoxy-propionic acid benzyl ester 
• 935887-90-4 C₁₉H₂₈N₂O₆ 
• 183793-49-9 (R)-tert-butyl 1-hydroxy-3-methoxy propan-2-yl carbamate 
• 134167-07-0 (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-methoxypropanoate 
• 1393176-84-5 [(S)-1-(4-fluoro-2-phenylaminophenylcarbamoyl)-2-methoxyethyl]carbamic acid tert-butyl ester 
• 1393177-57-5 {(S)-1-[3-(4-chlorophenyl)-3H-imidazo[4,5-b]pyridin-2-yl]ethyl}carbamic acid tert-butyl ester 
• 1312693-09-6 (R)-tert-butyl 1-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamate 

Relevant articles and documents

Process for preparation of optically pure N-substituted-3-methoxypropionic acid derivatives

A method of producing optically pure N-substituted-3-methoxy propionic acid is provided, which includes the steps of: reacting N-substituted-3-methoxy propionic acid represented by formula (III): with a chiral amine in a solvent to obtain a diastereomeric salt represented by formula (IV): subjecting the diastereomeric salt to a sequential washing process to obtain the optically pure N-substituted-3-methoxy propionic acid represented by one of formulae (Ia) and (Ib): wherein R1 is selected from the group consisting of C1-5 alkyl, C1-6 alkoxy and C6-10 aryloxy group, and R2 is selected from the group consisting of C2-5 alkyl, C6-8 cycloalkyl and C6-10 aryl.

Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors

The present application relates to novel fluorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof.

FUSED HETEROAROMATIC PYRROLIDINONES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.